EN

Your shopping cart

Amount

Total (VAT incl.)

VAT (21%)
Total
You have not added any reports to the cart yet.
Request reports
If you prefer to place your order via e-mail
contact us at: digital@azierta.com

Events and news

Blog
Home > Blog > Toxicology

Identification and quantification of impurities: a crucial aspect in pharmaceutical development

 

Introduction

Any component present in an active ingredient or in a finished product which is neither the active ingredient nor an excipient is considered an impurity. The presence of impurities, even in small amounts, may influence the efficacy and / or safety of the drug, hence the importance of their toxicological assessment and control.

Impurities classification

According to ICH regulations, impurities are classified as organic and inorganic impurities as well as residual solvents. Organic impurities may arise from the starting materials, by-products or reaction intermediates and from degradation products which may arise after synthetic accomplishment.  Inorganic impurities generally come from the synthetic process elements, such as some inorganic reagents, inorganic salts, metals, catalysts, ligands, etc…, while residual solvents are impurities derived from the use of solvents in the synthesis and purification steps.

While inorganic impurities or residual solvents are readily identified and their toxicity is known, in the case of organic impurities, their number and structural variability is unlimited and their toxicity generally unknown.

Analytical control and Qualification of organic impurities

Synthetic and degradation organic impurities analysis is controlled by a series of tests collected in the monographs of the European and / or American Pharmacopoeia1, whereas the ICH regulation establishes its limits according to the quantity of active principle or finished product that is administered to the day.

ICH regulation distinguishes three levels in the evaluation of impurities, the reporting threshold, the identification threshold and the qualification threshold. These thresholds are values from which the impurities must be reported, identified and qualified respectively. Qualification means the process of acquiring and evaluating the data that define the biological safety and toxicity of the impurity at the specified level.

Following the decision tree of the ICH Q3A2 and Q3B3 guidelines, when an impurity reaches or exceeds the level of qualification, the manufacturer must justify the toxicity of the product. In this sense and based on these guidelines, any impurity that has been adequately evaluated in clinical and / or safety studies will be considered qualified. Impurities that are described as metabolites in human or animal studies will also be qualified. Where levels of an impurity cannot be lowered below the qualification limit, an impurity safety study shall be carried out by means of a toxicological evaluation. In a worst-case scenario, the inclusion of additional experimental data on genotoxicity (Ames test or chromosomal aberration) and general toxicity (14 to 90 days toxicity assays) would be required, also accompanied by a toxicological assessment.

At Azierta, we are experts in toxicological evaluations of impurities. We have wide experience and our expert team certified by EUROTOX.

For further information visit: https://www.azierta.com/en/pharma/toxicology/extractables-lixiviables-impurities

References

 

  1. EDQM (European Directorate for the Quality of Medicines) EU. European Pharmacopoeia (Ph. Eur.) 9th Edition. (2017).
  2. ICH HARMONISED TRIPARTITE GUIDELINE. IMPURITIES IN NEW DRUG SUBSTANCES Q3A(R2). (2006).
  3. ICH HARMONISED TRIPARTITE GUIDELINE. IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2). (2006).

 

Back

Related posts

Polymeric materials in manufacturing processes: a new theat...

In the last few years, elastomer, thermoplastic or thermostable plastic polymeric materials have become established as basic...

Read more

Interview with Paulino Alonso: ICHQ3D on Elemental impurities...

ICHQ3D implementation involves a risk analysis to design strategies to control elemental impurities in drugs for human use,...

Read more

Leading innovation in pharma & health

100 professionals

Over 100 professionals

500 clients

Over 500 clients

9 year experience

9 years of experience

Innovation

Leading innovation

Client oriented

100% client oriented

We are at your complete disposal for any inquiry

Thank you for getting in touch! We will contact you as soon as possible to help you out
There has been an error while submitting your form, please try again, or call us at 912 77 10 76
Schedule appointment

Schedule a video call with our field experts

schedule
We use "cookies" to improve your experience on our site. Cookies enable us to tailor messages and display ads to your interests. They also help us understand how our site is being used. By continuing to use our site you consent to use our cookies.